• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

    10/21/25 6:46:00 AM ET
    $BLSH
    $DASH
    $FLY
    $IREN
    Finance: Consumer Services
    Finance
    EDP Services
    Technology
    Get the next $BLSH alert in real time by email

    Nine funds are single-stock leveraged ETFs seeking 200% long exposure

    NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, announced that it expects to launch nine new single stock leveraged ETFs on Thursday, October 23. The funds will be listed on Cboe, and each ETF aims to deliver twice (200%) the daily performance of its specific underlying stock.

    Expected Tradr launches:

    • Tradr 2X Long BLSH Daily ETF (Cboe: BLSX) – tracks Bullish Limited (NYSE:BLSH)
    • Tradr 2X Long DASH Daily ETF (Cboe: DASX) – tracks DoorDash, Inc. (NASDAQ:DASH)
    • Tradr 2X Long FLY Daily ETF (Cboe: FLYT) – tracks Firefly Aerospace, Inc. (NASDAQ:FLY)
    • Tradr 2X Long IREN Daily ETF (Cboe: IREX) – tracks IREN Limited (NASDAQ:IREN)
    • Tradr 2X Long NEM Daily ETF (Cboe: NWMX) – tracks Newmont Corporation (NYSE:NEM)
    • Tradr 2X Long OPEN Daily ETF (Cboe: OPEX) – tracks Opendoor Technologies Inc. (NASDAQ:OPEN)
    • Tradr 2X Long QS Daily ETF (Cboe: QSX) – tracks QuantumScape Corporation (NYSE:QS)
    • Tradr 2X Long SRPT Daily ETF (Cboe: SRPU) – tracks Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
    • Tradr 2X Long WULF Daily ETF (Cboe: WULX) – tracks TeraWulf, Inc. (NASDAQ:WULF)

    For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit www.tradretfs.com.

    The Prospectus for these funds is not yet effective or complete and may be changed. Tradr may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. The Prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any state where the offer of sale is not permitted.

    About Tradr ETFs

    Tradr ETFs are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.

    IMPORTANT RISK INFORMATION

    Tradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.

    Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.

    Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.

    The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.

    ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.

    ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

    Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting www.tradretfs.com. The Prospectus should be read carefully before investing.

    Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000769

    (PRNewsfoto/Tradr ETFs)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302589681.html

    SOURCE Tradr ETFs

    Get the next $BLSH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLSH
    $DASH
    $FLY
    $IREN

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Bullish
    $BLSH
    1/15/2026$55.00 → $52.00Buy
    Rosenblatt
    DoorDash Inc.
    $DASH
    1/14/2026$280.00Outperform
    BNP Paribas Exane
    IREN Limited
    $IREN
    1/13/2026$80.00Sell → Buy
    H.C. Wainwright
    TeraWulf Inc.
    $WULF
    12/31/2025$24.00Mkt Perform → Outperform
    Keefe Bruyette
    Firefly Aerospace Inc.
    $FLY
    12/19/2025Sector Weight
    KeyBanc Capital Markets
    IREN Limited
    $IREN
    12/18/2025$39.00Neutral
    Goldman
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    More analyst ratings

    $BLSH
    $DASH
    $FLY
    $IREN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ribar Geoffrey G was granted 36,102 shares (SEC Form 4)

    4 - QuantumScape Corp (0001811414) (Issuer)

    1/30/26 6:13:57 PM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 3 filed by new insider Ribar Geoffrey G

    3 - QuantumScape Corp (0001811414) (Issuer)

    1/30/26 6:11:33 PM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    Director Nicaise Claude exercised 10,500 shares at a strike of $13.71 and covered exercise/tax liability with 6,780 shares, increasing direct ownership by 13% to 31,532 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    1/29/26 8:05:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLSH
    $DASH
    $FLY
    $IREN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rosenblatt reiterated coverage on Bullish with a new price target

    Rosenblatt reiterated coverage of Bullish with a rating of Buy and set a new price target of $52.00 from $55.00 previously

    1/15/26 9:59:25 AM ET
    $BLSH
    Finance: Consumer Services
    Finance

    BNP Paribas Exane initiated coverage on DoorDash with a new price target

    BNP Paribas Exane initiated coverage of DoorDash with a rating of Outperform and set a new price target of $280.00

    1/14/26 8:40:46 AM ET
    $DASH
    EDP Services
    Technology

    $BLSH
    $DASH
    $FLY
    $IREN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Opendoor Technologies Inc

    SCHEDULE 13G/A - Opendoor Technologies Inc. (0001801169) (Subject)

    1/30/26 4:10:59 PM ET
    $OPEN
    Real Estate
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by TeraWulf Inc.

    SCHEDULE 13G/A - TERAWULF INC. (0001083301) (Subject)

    1/30/26 2:46:29 PM ET
    $WULF
    EDP Services
    Technology

    QuantumScape Corporation filed SEC Form 8-K: Leadership Update

    8-K - QuantumScape Corp (0001811414) (Filer)

    1/30/26 6:09:09 AM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    $BLSH
    $DASH
    $FLY
    $IREN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bucella Michael C. converted options into 35,487 shares and bought $50,178 worth of shares (4,178 units at $12.01), increasing direct ownership by 17% to 266,958 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    12/11/25 6:38:34 PM ET
    $WULF
    EDP Services
    Technology

    Director Lin Alfred bought $100,277,150 worth of shares (514,047 units at $195.07) (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    11/28/25 7:02:02 PM ET
    $DASH
    EDP Services
    Technology

    Chief Executive Officer Nejatian Kasra bought $1,004,562 worth of shares (125,000 units at $8.04), increasing direct ownership by 0.15% to 83,478,299 units (SEC Form 4)

    4 - Opendoor Technologies Inc. (0001801169) (Issuer)

    11/12/25 8:27:43 AM ET
    $OPEN
    Real Estate
    Finance

    $BLSH
    $DASH
    $FLY
    $IREN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opendoor 4Q25 Financial Open House: Opendoor to Report Fourth Quarter and Full Year 2025 Financial Results on February 19th, 2026

    SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor") (NASDAQ:OPEN) today announced that it will report fourth quarter and full year 2025 financial results for the period ended December 31, 2025 following the close of the market on Thursday, February 19, 2026. Modernizing Investor AccessOn February 19, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company's business and financial results. We believe in building in the open. The Financial Open House replaces the traditional earnings conference call with a video event, including a live segment for shareholder Q&A. Shareholder Q&AWe invi

    1/30/26 9:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    QuantumScape Welcomes Tech Industry Veteran Geoff Ribar to Board of Directors

    QuantumScape Corporation (NASDAQ:QS), a global leader in next-generation solid-state lithium-metal battery technology, today announced the appointment of Geoff Ribar to its board of directors. Ribar brings deep expertise and extensive leadership experience in the technology industry, with decades serving as CFO for companies across the sector. Ribar was Chief Financial Officer at Cadence Design Systems from 2010 to 2017 and previously served as CFO at Telegent Systems, Matrix Semiconductor and NVIDIA Corporation, among others. He was formerly Vice President and corporate controller at Advanced Micro Devices (AMD). He also serves on the board of directors at Acacia Research Corporation, Ev

    1/30/26 6:55:00 AM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    QuantumScape Announces Timing of Fourth Quarter 2025 Business Results and Webcast

    QuantumScape Corporation (NASDAQ:QS), a leader in developing next-generation solid-state lithium-metal batteries, today announced it will release its 2025 fourth-quarter business results after market close on Wednesday, February 11, 2026. This will be followed by a conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time). Siva Sivaram, chief executive officer, and Kevin Hettrich, chief financial officer, will participate on the call. Starting today, January 28, shareholders can submit questions (here) they would like addressed on the call. QuantumScape management will respond to a selection of the submitted questions. The company will accept questions until Tuesday, February 10, at 2

    1/28/26 4:15:00 PM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    $BLSH
    $DASH
    $FLY
    $IREN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLSH
    $DASH
    $FLY
    $IREN
    Leadership Updates

    Live Leadership Updates

    View All

    QuantumScape Welcomes Tech Industry Veteran Geoff Ribar to Board of Directors

    QuantumScape Corporation (NASDAQ:QS), a global leader in next-generation solid-state lithium-metal battery technology, today announced the appointment of Geoff Ribar to its board of directors. Ribar brings deep expertise and extensive leadership experience in the technology industry, with decades serving as CFO for companies across the sector. Ribar was Chief Financial Officer at Cadence Design Systems from 2010 to 2017 and previously served as CFO at Telegent Systems, Matrix Semiconductor and NVIDIA Corporation, among others. He was formerly Vice President and corporate controller at Advanced Micro Devices (AMD). He also serves on the board of directors at Acacia Research Corporation, Ev

    1/30/26 6:55:00 AM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    Milan Kovac Joins DoorDash Board of Directors

    DoorDash, Inc. (NASDAQ:DASH) announced today that Milan Kovac, former Vice President of Optimus Robotics and Autopilot at Tesla, has been appointed to the company's Board of Directors, effective January 16, 2026. Tony Xu, co-founder and CEO of DoorDash, Inc., said, "Milan has spent his career building and scaling ambitious engineering programs at the intersection of AI, autonomy, and robotics. He brings a rare combination of technical depth and operational leadership. That experience will be invaluable as we continue to build products and infrastructure that help local businesses grow, give consumers access to more of their communities, and create new ways for people to earn. I'm excited

    1/20/26 4:05:00 PM ET
    $DASH
    EDP Services
    Technology

    Opendoor Names President and CFO to Accelerate Next Chapter

    MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN) today announced two executive appointments designed to accelerate the Company's next phase of growth: President from the fintech frontier, and CFO promoted from within after an extensive external search. Accelerating our next chapter Lucas Matheson joins as President on December 22, 2025. Matheson most recently served as CEO of Coinbase Canada and previously spent five years at Shopify leading acceleration finance (M&A), strategic expansion, corporate financial planning & analysis and various operational roles. At Opendoor, Matheson will oversee Corporate Development, Financial Planning & Analysis, and em

    12/15/25 7:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    $BLSH
    $DASH
    $FLY
    $IREN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TeraWulf Inc.

    SC 13G/A - TERAWULF INC. (0001083301) (Subject)

    11/12/24 5:47:40 PM ET
    $WULF
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Newmont Corporation

    SC 13G/A - NEWMONT Corp /DE/ (0001164727) (Subject)

    11/12/24 4:43:51 PM ET
    $NEM
    Precious Metals
    Basic Materials

    $BLSH
    $DASH
    $FLY
    $IREN
    Financials

    Live finance-specific insights

    View All

    Opendoor 4Q25 Financial Open House: Opendoor to Report Fourth Quarter and Full Year 2025 Financial Results on February 19th, 2026

    SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor") (NASDAQ:OPEN) today announced that it will report fourth quarter and full year 2025 financial results for the period ended December 31, 2025 following the close of the market on Thursday, February 19, 2026. Modernizing Investor AccessOn February 19, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company's business and financial results. We believe in building in the open. The Financial Open House replaces the traditional earnings conference call with a video event, including a live segment for shareholder Q&A. Shareholder Q&AWe invi

    1/30/26 9:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    QuantumScape Announces Timing of Fourth Quarter 2025 Business Results and Webcast

    QuantumScape Corporation (NASDAQ:QS), a leader in developing next-generation solid-state lithium-metal batteries, today announced it will release its 2025 fourth-quarter business results after market close on Wednesday, February 11, 2026. This will be followed by a conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time). Siva Sivaram, chief executive officer, and Kevin Hettrich, chief financial officer, will participate on the call. Starting today, January 28, shareholders can submit questions (here) they would like addressed on the call. QuantumScape management will respond to a selection of the submitted questions. The company will accept questions until Tuesday, February 10, at 2

    1/28/26 4:15:00 PM ET
    $QS
    Industrial Machinery/Components
    Miscellaneous

    Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

    At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity-weighted external control group, as measured by Time to Rise (TTR) and 10-meter walk/run (10MWR). ELEVIDYS-treated patients showed an increasing treatment effect over time, with the functional gap versus the external control group significantly widening between Year 2 and Year 3 No new treatment-related safety signals were observed, consistent with the manageable safety profile observed with ELEVIDYS in ambulato

    1/26/26 8:00:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care